Skip to main content
. Author manuscript; available in PMC: 2011 Jul 1.
Published in final edited form as: Atherosclerosis. 2010 Feb 21;211(1):25–27. doi: 10.1016/j.atherosclerosis.2010.02.018

Table 1.

The effect of vitamin E vs. placebo stratified by Hp type on total CVD

Hp 1-1 Hp 2-1 Hp 2-2
N (vit E/placebo) 112 (56/56) 332 (159/173) 277 (146/131)
Absolute events n(%)
total CVD		 12(21.4%) vs. 10(17.9%)
Increase 19.6%		 37(23.3%) vs. 30(17.3%)
Increase 34.7%		 31( 21.2%) vs. 31(23.7%)
Decrease 10.5%
Adjusted total CVD
HR [95%CI]		 1.192 [0.456-3.117] 1.254 [0.766-2.055] 0.857 [0.511-1.435]

Total CVD defined as the composite endpoint comprising the first of any of these events: non fatal MI, non fatal stroke, cardiovascular death, PTCA or CABG.

HHS Vulnerability Disclosure